A recent case-control study suggests a protective role of lifetime estrogen exposure in progressive supranuclear palsy (PSP). Researchers evaluated the self-reported reproductive characteristics and estrogen of 150 women with PSP and 150 age-matched female controls who participated in the Environmental Genetic-PSP study. Conditional logistic regression models were generated to examine associations of PSP with estrogen. They found:
- There was no association between years of estrogen exposure duration and PSP.
- There was a suggestion of an inverse association between composite estrogen score and PSP that did not reach statistical significance.
- Any exposure to estrogen replacement therapy halved the risk of PSP.
- Among PSP cases, earlier age at menarche was associated with better performance on Hoehn and Yahr stage and Unified Parkinson's Disease Rating Scale II score at clinical examination.
Park HK, Ilango S, Charriez CM, et al. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. [Published online ahead of print February 20, 2018]. Mov Disord. doi:10.1002/mds.27336.
This Week's Must Reads
Global Burden of Brain and Other CNS Cancers, Lancet Neurol; ePub 2019 Feb 20; GBD 2016 Brain and Other CNS Cancer Collaborators
Ethnoracial Differences Found in Alzheimer Disease, Alzheimers Dement; ePub 2019 Feb 18; Santosa, et al
Must Reads in Movement Disorders
Tourette, CTD, and Cardiometabolic Disorders Link, JAMA Neurology; ePub 2018 Jan 14; Brander, et al
Study Compares 2 Cognitive Assessment Tools, Mov Disord; ePub 2018 Dec 10; Hendershott, et al
White Matter Differences Between ET and PD, Neurology; ePub 2018 Nov 30; Juttukonda, et al
Physical Activity and Clinical Progression in PD, Parkinsonism Relat Disord; ePub 2018 Dec 10; Amara, et al
Analyzing the Spectrum of Visual Symptoms in PD , Front Neurol; ePub 2018 Nov 27; Barrell, et al